-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the "New England Journal of Medicine" recently published an important real-world study from Public Health England.
Based on the data from the HOSTED data set, the researchers included data on more than 365,000 households and more than 1 million household contacts where the first case of infection occurred in the UK between January 4 and February 28, 2021.
The research team compared and evaluated the infection 21 days after vaccination with at least one dose of the vaccine (ChAdOx1 nCoV-19 or BNT162b2).
If the first infected person in the family has not been vaccinated, the secondary infection rate of family members is 10.
In contrast, if the first infected person received at least one dose of ChAdOx1 nCoV-19 vaccine, the secondary infection rate of family members was 5.
If the first infected person received at least one dose of BNT162b2 vaccine, the secondary infection rate of family members was 6.
Based on these British real-world data, the paper points out that overall, 21 days after vaccination with at least one dose of ChAdOx1 nCoV-19 vaccine or BNT162b2 vaccine, if infection occurs, the risk of transmission to family members is reduced by about 40%-50%.
Among the data analyzed, most (93%) of the first cases of infection in families who had been vaccinated received only the first dose
The research team added that the collected data only contained case diagnosis information and lacked information on the symptoms or viral load of the infected person
In addition, the impact of two doses of vaccine on the spread of the virus needs to be evaluated in the future
Reference
[1] Ross J.